TNFα remained stable at 6 months and at 12 months post-AHSCT compared to baseline in NHL patients, whereas in MS patients TNFα was significantly increased at 6 months and 24 months post-AHSCT. The gene discussed is TNF; the disease is myeloid sarcoma.